
    
      Bioequivalence study of Rivastigmine Capsules 1.5 mg and Exelon 1.5 mg This was a single
      center, single-dose, open-label, randomized, 2-way crossover bioequivalence study,performed
      under fed conditions. The treatment phases were separated by a washout period of 7 days.
    
  